Pharmacokinetic/Pharmacodynamic model in pregnant women with depression to guide sertraline dosing
Pharmacokinetic/Pharmacodynamic model in pregnant women with depression to guide sertraline dosing
批准号:
10390578
负责人:
ANGELA K BIRNBAUM
金额:
$22.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-08-18 至 2024-07-31
关键词:
37 weeks gestationAddressAdmission activityAdverse effectsAffectAntidepressive AgentsAnxietyApgar ScoreAreaBeck depression inventoryBirthBirth WeightCYP2C19 geneCYP2C9 geneCYP2D6 geneCYP3A4 geneCaringCharacteristicsClinicalClinical Practice GuidelineCollaborationsCytochrome P450DataDatabasesDevelopmentDiscipline of obstetricsDiseaseDoseDrug ExposureDrug KineticsEnzymesEquilibriumExposure toFetusFosteringFoundationsGestational AgeGoalsHamilton Rating Scale for DepressionHeightHypoglycemiaIndividualInvestigationKnowledgeLeadLength of StayLow Birth Weight InfantMaternal HealthMaternal and Child HealthMeasuresMental DepressionMental HealthMetabolismModelingNeonatalNeonatal Intensive Care UnitsOralOutcomeOxygenPharmaceutical PreparationsPharmacologyPhysiologicalPhysiologyPopulationPostpartum DepressionPostpartum PeriodPregnancyPregnant WomenPremature BirthResearchResourcesSample SizeSelective Serotonin Reuptake InhibitorSertralineSmall for Gestational Age InfantSymptomsTimeUniversitiesVisitWeightWomanadverse outcomeantidepressant effectbiobankcareer developmentdepressive symptomsdisorder preventionevidence baseimprovedindividualized medicineinter-individual variationneonatal outcomeneuropsychiatryperinatal outcomesperinatal periodpersonalized medicinepharmacodynamic modelpregnantprepregnancypreventprimary outcomeprogramsprospectivereproductiveresponsetreatment planning
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Depression and anxiety during pregnancy affect over 10% of women with 6-8% of pregnant women receiving a
prescription for a selective serotonin reuptake inhibitor (SSRI) antidepressant. Sertraline is the most commonly
prescribed SSRI in women of reproductive years. However, there remains limited information for optimizing its
treatment during pregnancy. Sertraline shows large inter-individual variability although studies generally suffer
from small sample sizes and inconsistent observations. Physiological changes accompanying pregnancy can
alter drug pharmacokinetics (e.g., clearance) which can significantly affect steady-state concentrations of
medications, supporting the need for dose adjustments in order to maintain pre-pregnancy drug exposure. Our
objective is to quantify the contribution of sertraline pharmacokinetic exposure to maternal health and
obstetrical/neonatal outcomes. The Women’s Mental Health Program database contains prospectively
collected data from more than 2,500 individuals with neuropsychiatric illnesses across more than 15,000
unique visits during the perinatal and postpartum periods. Sertraline and metabolite concentrations along with
maternal symptoms and obstetrical/neonatal outcome information will be analyzed via
pharmacokinetic/pharmacodynamic modeling enabling characterization of the relationships between changes
in sertraline exposure with maternal symptoms of depression and neonatal outcomes during pregnancy and
postpartum. Results from this project will support refinement of dosing strategies and evidence-based
personalized treatment planning for the use of sertraline during pregnancy. The application of pharmacokinetic-
guided dosing will result in enhanced prevention of disease-related symptoms and improved maternal and
child health. This project will provide the foundation for investigation of other antidepressants and psychotropic
medications used during pregnancy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pharmacokinetic/Pharmacodynamic model in pregnant women with depression to guide sertraline dosing
-
批准号:10685934
-
项目类别:
-
资助金额:$18.92万
-
财政年份:2022
-
负责人:ANGELA K BIRNBAUM
-
依托单位:
Physiological-based Pharmacokinetics Approach to Determine the Extent of Drug Exposure of Antiseizure Medications During Pregnancy and Breastfeeding
-
批准号:10461805
-
项目类别:
-
资助金额:$55.04万
-
财政年份:2021
-
负责人:ANGELA K BIRNBAUM
-
依托单位:
Clinical Impact of Unstable AED Levels in Elderly Nursing Home Epilepsy Patients
-
批准号:7319735
-
项目类别:
-
资助金额:$34.48万
-
财政年份:2007
-
负责人:ANGELA K BIRNBAUM
-
依托单位:
Clinical Impact of Unstable AED Levels in Elderly Nursing Home Epilepsy Patients
-
批准号:7676030
-
项目类别:
-
资助金额:$38.81万
-
财政年份:2007
-
负责人:ANGELA K BIRNBAUM
-
依托单位:
Clinical Impact of Unstable AED Levels in Elderly Nursing Home Epilepsy Patients
-
批准号:8130874
-
项目类别:
-
资助金额:$38.77万
-
财政年份:2007
-
负责人:ANGELA K BIRNBAUM
-
依托单位:
Clinical Impact of Unstable AED Levels in Elderly Nursing Home Epilepsy Patients
-
批准号:7917240
-
项目类别:
-
资助金额:$41.85万
-
财政年份:2007
-
负责人:ANGELA K BIRNBAUM
-
依托单位:
Clinical Impact of Unstable AED Levels in Elderly Nursing Home Epilepsy Patients
-
批准号:7487847
-
项目类别:
-
资助金额:$38.44万
-
财政年份:2007
-
负责人:ANGELA K BIRNBAUM
-
依托单位:
PHARMACOEPIDEMIOLOGY OF THE ANTIEPILEPTIC DRUGS
-
批准号:7119180
-
项目类别:
-
资助金额:$33.45万
-
财政年份:2005
-
负责人:ANGELA K BIRNBAUM
-
依托单位:
PHARMACOEPIDEMIOLOGY OF THE ANTIEPILEPTIC DRUGS
-
批准号:6666466
-
项目类别:
-
资助金额:$29.76万
-
财政年份:2002
-
负责人:ANGELA K BIRNBAUM
-
依托单位:
PHARMACOEPIDEMIOLOGY OF THE ANTIEPILEPTIC DRUGS
-
批准号:7281604
-
项目类别:
-
资助金额:$33.45万
-
财政年份:--
-
负责人:ANGELA K BIRNBAUM
-
依托单位:
海外基金